AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Recurrent Head & Neck Cancer Squamous Cell Carcinoma - 2019 Pipeline Insight Study - ResearchAndMarkets.com

May 8, 2019

DUBLIN--(BUSINESS WIRE)--May 8, 2019--The “Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Recurrent Head And Neck Cancer Squamous Cell Carcinoma development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

  • The report provides a snapshot of the pipeline development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
  • The report also covers the dormant and discontinued pipeline projects related to Recurrent Head And Neck Cancer Squamous Cell Carcinoma

Reasons to Buy

  • Establish comprehensive understanding of the pipeline activity across this Recurrent Head And Neck Cancer Squamous Cell Carcinoma to formulate effective R&D strategies
  • Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Recurrent Head And Neck Cancer Squamous Cell Carcinoma therapeutics
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • Advaxis
  • Amgen Inc.
  • AstraZeneca PLC
  • AVEO Pharmaceuticals
  • Critical Outcome Technologies Inc.
  • Daiichi Sankyo Company
  • Genentech
  • Glycotope GmbH
  • Immunovative Therapies
  • Laboratoires Pierre Fabre S.A.
  • Mabion S.A.
  • MedImmune
  • Merck & Co.
  • Novartis AG
  • Oncolytics Biotech Inc.
  • Ono Pharmaceutical Co.
  • Panacea Biotec Limited

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/r79vvk

View source version on businesswire.com:https://www.businesswire.com/news/home/20190508005695/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs ,Skin Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/08/2019 01:29 PM/DISC: 05/08/2019 01:29 PM

http://www.businesswire.com/news/home/20190508005695/en